Navigation Links
NEBA Health Releases Key Study Results for the first FDA approved brain wave test to help clinicians assess ADHD in children and adolescents
Date:7/22/2013

AUGUSTA, Ga., July 22, 2013 /PRNewswire/ -- NEBA Health, LLC releases today key study results regarding the FDA approval of NEBA®, the first brain wave test to help clinicians assess ADHD in children and adolescents.  FDA cleared NEBA for marketing on July 15, 2013.

About NEBA
NEBA integrates an ADHD biomarker together with a clinician's ADHD evaluation. In other words, NEBA is not used as a stand-alone diagnostic. The clinician still conducts their ADHD evaluation as in their regular practice using their usual assessment tools. Once the clinician determines that ADHD-like symptoms are present, NEBA helps the clinician to determine whether the symptoms are due to ADHD, or due to another condition. NEBA does this using EEG to separate ADHD patients into biomarker-based groups with clinical differences that allow validated recommendations to be offered to the clinicians.

Because ADHD symptoms overlap with other diagnoses, there may be difficulty for the clinician to determine whether ADHD is the primary cause, whether ADHD symptoms are secondary to other diagnoses, or whether ADHD is comorbid with other diagnoses. Dr. Steve Snyder, Vice President of Research and Development said, "NEBA can help the clinician to confirm ADHD as primary diagnosis, and can help the clinician to determine whether ADHD-like symptoms may be better explained by another primary condition."

About NEBA accuracy
Previous studies have supported that a multidisciplinary team of clinicians is better able than an individual clinician to determine if ADHD-like symptoms are due to another primary condition. Similarly in the NEBA Clinical Investigation reviewed by the FDA, a triple-blinded protocol showed only 61% agreement between individual clinicians and a multidisciplinary team. The investigation also showed that a clinician could use NEBA to improve accuracy from 61% to 88%.  (Study results are posted at http://www.nebahealth.com/results.htm)

Dr. Snyder said, "Our study supports that a clinician using NEBA as one part of a full ADHD evaluation would be more likely to converge upon diagnostic evaluation results of a multidisciplinary team."

About NEBA costs
Using NEBA will lead to cost savings. Dr. Snyder said, "Whereas NEBA adds some upfront costs, it does reduce overall costs in the long term by significantly reducing misdiagnosis." NIH/HHS awarded the company a Qualifying Therapeutic Discovery Project grant in October of 2010 based in part on NEBA's potential to be cost saving.

Howard Merry, President, said, "Introducing NEBA in the United States is the culmination of seven years of dedicated work with FDA and follows our CE marking in Europe and Health Canada licensing. Our small team has been together for the entire duration of this project and we are committed to helping clinicians, children, and families."

About NEBA Health
NEBA Health is focused on Neuropsychiatric Interpretive EEG Assessment Aids. We have ongoing work in ADHD, depression and dementia. Our first product - eponymously named NEBA - is an ADHD assessment aid cleared for marketing in the USA (K112711), as well as CE marked and Health Canada licensed.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. inVentiv Health Selected to Provide Sales Operations Support for Santarus
6. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
7. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
8. Nations Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey
9. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
10. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
11. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation President ... and Astronomy, has been selected for membership in ARCS Alumni Hall of Fame ... Prize in Fundamental physics for the discovery of the accelerating expansion of the universe, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):